[1] Cavassani KA,Carson WF,Moreira AP,et al. The post sepsis-induced expansion and enhanced function of regulatory T cells create an environment to potentiate tumor growth[J]. Blood,2010,115(22):4403-4411. [2] Raychaudhuri B,Rayman P,Ireland J,et al. Myeloidderived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma[J]. Neuro Oncol,2011, 13(6):591-599. [3] Talmadge JE. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy[J]. Clin Cancer Res, 2007,13(18 Sup 1):5243-5248. [4] Gabrilovich DI,Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system[J]. Nat Rev Immunol,2009, 9(3):162-174. [5] Bronte V,Serafini P,Apolloni E,Zanovello P. Tumorinduced immune dysfunctions caused by myeloid suppressor cells[J]. J Immunother,2001,24(6):431-446. [6] Albeituni SH,Ding C,Yan J. Hampering immune suppressors:therapeutic targeting of myeloid-derived suppressor cells in cancer[J]. Cancer J,2013,19(6):490-501. [7] Almand B,Clark JI,Nikitina E,et al. Increased production of immature myeloid cells in cancer patients:a mechanism of immunosuppression in cancer[J]. J Immunol,2001,166(1):678-689. [8] Filipazzi P,Huber V,Rivoltini L. Phenotype,function and clinical implications of myeloid-derived suppressor cells in cancer patients[J]. Cancer Immunol Immunother,2012,61(2):255-263. [9] Nagaraj S,Youn JI,Weber H,et al. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer[J]. Clin Cancer Res, 2010,16(6):1812-1823. [10] Zhang H,Maric I,DiPrima MJ,et al. Fibrocytes represent a novel MDSC subset circulating in patients with metastatic cancer[J]. Blood,2013,122(7):1105-1113. [11] Lin Y,Gustafson MP,Bulur PA,et al. Immunosuppressive CD14+HLA-DRlow/- monocytes in B-cell non-Hodgkin lymphoma[J]. Blood,2011,117(3):872-8781. [12] Sander LE,Sackett SD,Dierssen U,et al. Hepatic acutephase proteins control innate immune responses during infection by promoting myeloid-derived suppressor cell function[J]. J Exp Med,2010,207(7):1453-1464. [13] Ko JS,Rayman P,Ireland J,et al. Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained[J]. Cancer Res, 2010,70(9):3526-3536. [14] Montero AJ,Diaz-Montero CM,Kyriakopoulos CE,et al. Myeloid-derived suppressor cells in cancer patients:a clinical perspective[J]. J Immunother,2012,35(2):107-115. [15] Gorgun GT,Whitehill G,Anderson JL,et al. Tumorpromoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans[J]. Blood,2013,121(15):2975-2987. [16] Chen MF,Kuan FC,Yen TC,et al. IL-6-stimulated CD11b+ CD14+HLA-DR- myeloid-derived suppressor cells,are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus[J]. Oncotarget,2014,5(18):8716-8728. [17] Rudolph BM,Loquai C,Gerwe A,et al. Increased frequencies of CD11b+CD33+CD14+HLA-DRlow myeloid-derived suppressor cells are an early event in melanoma patients[J]. Exp Dermatol,2014,23(3):202-204. [18] Huang A,Zhang B,Wang B,et al. Increased CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients[J]. Cancer Immunol Immunother,2013, 62(9):1439-1451. [19] Khaled YS,Ammori BJ,Elkord E. Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients[J]. J Immunol Res,2014,2014:879897. [20] Wang Z,Zhang L,Wang H,et al. Tumor-induced CD14+HLA-DR-/low myeloid-derived suppressor cells correlate with tumor progression and outcome of therapy in multiple myeloma patients[J]. Cancer Immunol Immunother, 2015, 64(3):389-399. [21] Alizadeh D1,Trad M,Hanke NT,et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer[J].Cancer Res,2014,74(1):104-118. [22] Cripps JG,Gorham JD. MDSC in autoimmunity[J]. Int Immunopharmacol,2011,11(7):789-793. |